Jury favors Amgen in PCSK9 patent case

A jury upheld two patents from Amgen Inc. (NASDAQ:AMGN) covering mAbs against PCSK9 in the company's patent infringement suit against Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY). The case was argued in the U.S. District Court for the District of Delaware.

Both parties acknowledged that Praluent alirocumab, a mAb against PCSK9 marketed by Sanofi and Regeneron, infringed claims in both patents, but Sanofi and Regeneron argued the patents were invalid. Amgen markets PCSK9 drug Repatha evolocumab. ...